<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>23 Transplant • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="23 Transplant • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/23 Transplant/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/23 Transplant/" />

<link rel="stylesheet" href="/wiki/style.css" />

  </head>
  <body>
    <div
      class="fixed top-0 w-screen px-4 py-4 md:px-10 bg-slate-200 bg-opacity-90"
    >
    <div class="flex items-center justify-between max-w-6xl mx-auto">
      <a href="/wiki/" title="Home">
        <img src="/wiki/assets/avatar.png" class="w-10 h-10 " />
      </a>

      <nav class="flex space-x-2 uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>
    <div class="mx-auto">

    <div class="flex items-center justify-center max-w-full px-6 mt-32 mb-32">
      <div  class="prose">
<article><h1>23 Transplant</h1>
<!-- heart transplant indications.. -->
<p>Heart transplantation is performed on patients with end-stage heart failure or severe coronary artery disease. Indications for heart transplant include:</p>
<ul>
<li><strong>Severe cardiac disability on maximal medical therapy</strong></li>
<li><strong>Symptomatic ischemia or recurrent ventricular arrhythmia on maximum medical therapy, with left ventricular ejection fraction less than 30%</strong></li>
<li><strong>Unstable angina and not a candidate for CABG or percutaneous transluminal coronary angioplasty</strong></li>
</ul>
<!-- heart transplant matching depends on, CI.. -->
<p>Donor matching is based on several donor-recipient compatibilities including:</p>
<ul>
<li><strong>ABO compatibility</strong></li>
<li><strong>Body size</strong></li>
<li><strong>Weight similarity</strong></li>
</ul>
<p>Contraindications for heart transplantation include:</p>
<ul>
<li><strong>Pulmonary hypertension</strong></li>
<li><strong>Smoking tobacco within six months</strong></li>
<li><strong>COPD</strong></li>
</ul>
<!-- heart transplant type of rejection, diagnosis how.. -->
<p><strong>Acute rejection</strong> is the most common form of rejection following heart transplantation.</p>
<p>Rejection is diagnosed and conﬁrmed by <strong>endomyocardial biopsy via the right internal jugular vein.</strong></p>
<!-- heart transplant complications.. -->
<p>The complications of heart transplantation include:</p>
<ul>
<li><strong>Infection</strong></li>
<li><strong>Pulmonary hypertension</strong></li>
<li><strong>Graft failure</strong></li>
</ul>
<h1>Lung Transplant</h1>
<!-- ignore.. -->
<p>Lung transplantation is performed on patients with <strong>end-stage lung disease who are refractory to all other available medical treatments, most commonly secondary to:</strong></p>
<ul>
<li><strong>COPD</strong></li>
<li><strong>Idiopathic pulmonary fibrosis</strong></li>
<li><strong>Cystic fibrosis</strong></li>
<li><strong>Primary pulmonary hypertension</strong></li>
<li><strong>α1-antitrypsin deficiency</strong></li>
</ul>
<!-- lung transplant compatibility, CI.. -->
<p>Donor-recipient compatibility for lung transplantation is based upon several criteria:</p>
<ul>
<li><strong>ABO compatibility</strong></li>
<li><strong>Pulmonary gas exchange</strong></li>
<li><strong>No smoking history</strong></li>
<li><strong>Similar donor-recipient lung volumes</strong></li>
</ul>
<p>Contraindications for lung transplantation include:</p>
<ul>
<li><strong>Smoking within six months</strong></li>
<li><strong>Cardiac, renal, or hepatic failure</strong></li>
<li><strong>HIV</strong></li>
<li><strong>Terminal illness</strong></li>
</ul>
<!-- lung transplant type of rejection, diagnosis how.. -->
<p><strong>Chronic rejection</strong> is the most common form of rejection following lung transplantation.</p>
<p>Rejection is <strong>confirmed by biopsy through bronchoscopy</strong> and has several findings including:</p>
<ul>
<li><strong>Fever</strong></li>
<li><strong>Dyspnea</strong></li>
<li><strong>Decreased PaO2</strong></li>
<li><strong>Decreased FEV1</strong></li>
<li><strong>Chest x-ray demonstrating interstitial infiltrate</strong></li>
</ul>
<!-- ignore.. -->
<p>Complications following lung transplantation include:</p>
<ul>
<li><strong>Infection</strong></li>
<li><strong>Rejection</strong></li>
</ul>
<h1>Immunosuppression</h1>
<p>All patients receiving allografts require immunosuppressive therapy. The only exception is <strong>recipients of a transplanted organ from an identical monozygotic twin</strong> (isograft).</p>
<p>Most immunosuppressive agents covered in this topic are used in <em>maintenance therapy</em> to prevent <strong>acute rejection</strong> of the graft.</p>
<p>Immunosuppressive agents carry a complex array of morbidities. The most important morbidities to broadly associate with the various immunosuppressive agents are <strong>nephrotoxicity</strong>, <strong>myelosuppression,</strong> and <strong>metabolic syndrome</strong>.</p>
<p>Glucocorticoids suppress B and T cell function and inhibit the release of IL-1 from macrophages. <strong>Prednisone</strong> is the most commonly used glucocorticoid used in transplantation.</p>
<p>The adverse effects of glucocorticoids include:</p>
<ul>
<li><strong>Cushing syndrome</strong></li>
<li><strong>Cataracts</strong></li>
<li><strong>Dyspepsia</strong></li>
<li><strong>Osteonecrosis</strong></li>
<li><strong>Acne</strong></li>
<li><strong>Glucose intolerance</strong></li>
</ul>
<p>Cyclosporine (CsA, Sandimmune, Neoral, Gengraf) is a <strong>calcineurin inhibitor</strong> that binds cyclophilin and <strong>inhibits the secretion and formation of IL-2</strong>.</p>
<p>Tacrolimus (FK506, Prograf) is a <strong>calcineurin inhibitor</strong> that binds FK506 binding protein (FKBP**)** and <strong>inhibits the secretion and formation of IL-2</strong> and other cytokines. It is the most commonly used calcineurin inhibitor in immunosuppressive drug regimens.</p>
<p>In contrast to cyclosporine (another commonly-used calcineurin inhibitor), tacrolimus exhibits less severe <strong>androgenic effects</strong>.</p>
<p>Azathioprine (Imuran) is an antimetabolite precursor of 6-mercaptopurine, which <strong>inhibits nucleotide synthesis</strong>. It is being replaced with mycophenolate mofetil (MMF, CellCept).</p>
<p>Sirolimus or rapamycin (Rapamune) exhibits a unique molecular target by <strong>inhibiting mTOR</strong> (mammalian Target Of Rapamycin) by <strong>complexing with FKBP to inhibit T-cell proliferation</strong>.</p>
<p><strong>Sirolimus</strong> is unique for exhibiting minimal nephrotoxicity.</p>
<p>Muromonab-CD3 (Orthoclone OKT3) is a <strong>monoclonal antibody that depletes the T-cell population</strong>.</p>
<p>Muromonab-CD3 can induce a <strong>one-time cytokine release</strong> (fever, bronchospasm) upon use. It can only be used in short-term therapy.</p>
<h1>Kidney Transplant</h1>
<p>**Kidney transplantation **is the most common solid organ to be transplanted.</p>
<p>There are multiple causes of end stage renal disease that may warrant transplantation including:</p>
<ul>
<li><strong>Diabetes</strong></li>
<li><strong>Hypertension</strong></li>
<li><strong>Glomerular nephritis</strong></li>
<li><strong>Congenital urologic anomalies</strong></li>
<li><strong>Focal segmental glomerular sclerosis</strong></li>
</ul>
<p>Existing kidneys are NOT removed due to increased rates of surgical morbidity. The donated kidney is usually placed in the iliac fossa (pelvis).</p>
<p><strong>Left kidney</strong> is preferred as a donor because it has a longer renal vein (remember the inferior vena cava is on the right side of the body, so the left kidney needs a longer vein).</p>
<!-- kidney transplant early, late complications.. -->
<p>Early complications of kidney transplant include oliguria or anuria that may result from <strong>graft thrombosis</strong> or <strong>urine leak.</strong></p>
<p>Late complications of kidney transplant include <strong>ureteral stricture (↑ creatinine)</strong> and <strong>arteriosclerosis of the renal artery</strong>.</p>
<h1>Pancreas Transplant</h1>
<!-- pancreas transplant when, CI.. -->
<p>Pancreas transplantation is performed on individuals with <strong>type 1 diabetes with end-stage renal disease</strong> (majority of these are simultaneous pancreas-kidney transplantations).</p>
<p><strong>Type II diabetes</strong> is a contraindication to pancreas transplantation.</p>
<h1>Liver Transplant</h1>
<!-- ignore.. -->
<p>There are multiple causes of liver failure that are indications for transplantation:</p>
<ul>
<li><strong>Chronic hepatitis B</strong></li>
<li><strong>Chronic hepatitis C</strong></li>
<li><strong>Alcoholic sclerosis</strong></li>
<li><strong>Biliary disease</strong> - primary sclerosing cholangitis, primary biliary cirrhosis, biliary atresia</li>
<li><strong>Wilson disease</strong></li>
</ul>
<!-- liver transplant CI.. -->
<p>Absolute contraindications for liver transplantation include:</p>
<ul>
<li><strong>Active drug or alcohol abuse</strong></li>
<li><strong>Uncontrolled metastatic cancer outside liver</strong></li>
<li><strong>Hepatocellular carcinoma with metastases</strong></li>
<li><strong>Active systemic infection</strong></li>
</ul>
<p><strong>Individuals with hepatitis B or C</strong> may be used as donors for patients with the same infection if there is no organ damage detected in the donor liver.</p>
<h1>Transplant Selections</h1>
<!-- organ donors selection, compatibility selection.. -->
<p>Organ transplant donors are most commonly <strong>brain-dead or living voluntary donors without cancer, sepsis, or organ insufficiency</strong>. HIV is no longer an absolute contraindication for transplantation; patients with a well-controlled HIV infection are eligible.</p>
<p>Selection of organ transplant donors is based on the following criteria:</p>
<ul>
<li><strong>ABO blood group compatibility</strong></li>
<li><strong>Cross match compatibility</strong> (i.e. antidonor antibodies on recipient T cells)</li>
<li><strong>HLA antigen matching</strong></li>
</ul>
<p>HLA antigen matching is <strong>more significant</strong> for <strong>pancreas</strong> and <strong>kidney</strong> transplants and less significant for <strong>heart</strong> and <strong>liver</strong>.</p>
<!-- organs with infection can be transplanted?.. -->
<p>Organs from individuals with a specific infection (e.g. hepatitis) with <strong>no significant organ damage</strong> may be transplanted into a <strong>recipient with the same infection</strong>.</p>
<h1>Transplant Rejection</h1>
<!-- 3 types of transplant rejection, time, pathogenesis, treatment.. -->
<p>The three types of transplant rejection are:</p>
<ul>
<li><strong>Hyperacute</strong></li>
<li><strong>Acute</strong></li>
<li><strong>Chronic</strong></li>
</ul>
<p>Hyperacute transplant rejection occurs <strong>immediately or within hours (&lt; 24 hours)</strong> of the transplantation.</p>
<p><strong>Preformed recipient antibodies against donor tissue</strong>, usually directed toward ABO blood group or HLA antigens, mediate the reaction leading to vascular thrombosis and necrosis. Histologically, the predominant cell infiltrate of hyperacute transplant rejection is <strong>polymorphonuclear leukocytes</strong>.</p>
<p>Hyperacute transplant rejection is <strong>untreatable</strong>, but rarely occurs due to <strong>cross-matching</strong> and <strong>blood group matching</strong>.</p>
<p>Acute transplant rejection usually occurs <strong>7-10 days</strong> after transplantation, but may occur up to a year.</p>
<p><strong>Antidonor T-cells proliferate in the recipient</strong> and mediate the reaction leading to mononuclear infiltration into vascular and interstitial spaces. For this reason, histologically, the predominant cell infiltrate of acute transplant rejection is <strong>monocyte/macrophage</strong>.</p>
<p>Acute transplant rejection is treated with <strong>intravenous steroids</strong> (e.g. <strong>methylprednisolone</strong>) and is <strong>frequently reversible</strong>. If reversed, the graft has a good prognosis.</p>
<p>Chronic transplant rejection occurs <strong>years after transplantation</strong>.</p>
<p>The pathogenesis of chronic transplant rejection is poorly understood, but is <strong>mediated by both cellular and humoral immune reactions</strong>. The donor tissue is characterized by <strong>vascular intimal hyperplasia</strong> and <strong>lymphocytic infiltration</strong>.</p>
<p>There is <strong>no effective treatment</strong> for chronic transplant rejection.</p>
</article>
<hr />
<p>Backlinks</p>

<p>No backlinks found.</p>


</div>
    </div>

    <!-- <hr />
<p>Backlinks</p>

<p>No backlinks found.</p>

 -->

    <footer>
      <div class="max-w-6xl mb-10 text-sm text-center mt-96 ">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
